Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Pharvaris | 2026 | Post-IPO Equity | Undisclosed | Zug |
| Cabaletta Bio | 2026 | Post-IPO Equity | Undisclosed | Philadelphia |
| Quince Therapeutics | 2026 | Post-IPO Equity | Undisclosed | South San Francisco |
| GH Research | 2026 | Post-IPO Equity | Undisclosed | Dublin |
| Climb Bio | 2026 | Post-IPO Equity | Undisclosed | Redmond |
| Terremoto Biosciences | 2026 | Series C | Undisclosed | San Francisco |
| Solid Biosciences | 2026 | Post Ipo Equity | $240.0M | Charlestown |
| Tessera Therapeutics | 2026 | Grant | Undisclosed | Cambridge |
| Star Therapeutics | 2025 | Series D | $125.0M | South San Francisco |
| Ensoma | 2025 | Venture - Series Unknown | $53.0M | Boston |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | Pharvaris | Post-IPO Equity | Undisclosed | Zug, Switzerland |
| 2 | Cabaletta Bio | Post-IPO Equity | Undisclosed | Philadelphia, United States |
| 3 | Quince Therapeutics | Post-IPO Equity | Undisclosed | South San Francisco, United States |
| 4 | GH Research | Post-IPO Equity | Undisclosed | Dublin, Ireland |
| 5 | Climb Bio | Post-IPO Equity | Undisclosed | Redmond, United States |
| 6 | Terremoto Biosciences | Series C | Undisclosed | San Francisco, United States |
| 7 | Solid Biosciences | Post Ipo Equity | $240.0M | Charlestown, United States |
| 8 | Tessera Therapeutics | Grant | Undisclosed | Cambridge, United States |
| 9 | Star Therapeutics | Series D | $125.0M | South San Francisco, United States |
| 10 | Ensoma | Venture - Series Unknown | $53.0M | Boston, United States |
Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Quince Therapeutics is developing treatments for Alzheimer's and other degenerative disorders.
GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.
Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.
Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.
Tessera Therapeutics develops gene writing technology designed to modify DNA sequences within human cells for therapeutic use.
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.
Tioga Cardiovascular is a healthcare company providing valve replacement solutions for mitral and tricuspid applications.
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.
Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Triveni Bio is a a biotech company that develops functional antibodies targeting immunological and inflammatory disorders.
858 Therapeutics develops small molecule drugs targeting oncology and immunology.
GC Therapeutics uses synthetic biology to program patient-derived stem cells into various cell types in an efficient and scalable manner.
Moximed develops innovative therapies for patients with knee osteoarthritis.
Adona Medical is a technology-based company that designs and develops heart failure management systems to improve heart care.
Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas.
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.
BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3K malignancies.
Synnovation Therapeutics is a precision oncology company that develops therapeutics that aims to help people with cancer.
Nexo Therapeutics offers treatments for some of cancer's most intractable targets.
Cormorant Asset Management has invested in 134 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 13 different industry categories.
Among tracked funding rounds, Solid Biosciences received $240.0M in a Post Ipo Equity round. Cormorant Asset Management's total known invested capital is $12.5B.
Cormorant Asset Management's average investment size is $116.4M across its portfolio of 134 companies.
Recent Cormorant Asset Management portfolio additions include Pharvaris, Cabaletta Bio, Quince Therapeutics, GH Research, Climb Bio. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors